Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III StudyLin Shen, Zhiyong He, Xinmin Yu et al.|Journal of Clinical Oncology|2022Cited by 306
Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinomaYang Zhang, Rui‐Hua Xu, Miao‐Zhen Qiu et al.|Cell Reports Medicine|2022Cited by 51
PPM1D Functions as Oncogene and is Associated with Poor Prognosis in Esophageal Squamous Cell CarcinomaKe Li, Jufeng Wang, Ying Liu et al.|Pathology & Oncology Research|2018Cited by 27